Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteActive in the last 2 years

Makiko Urabe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-8033-3158; OpenAlex author ID A5003004193. Sources: OpenAlex.

Their work

Papers
19
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 3 papers · 2024: 3 papers · 2025: 2 papers · 2026: 6 papers

Papers 19

  1. Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment. Co-author DOI 10.1002/cnr2.70492↗
  2. Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab-Paclitaxel as First-Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic C… Co-author DOI 10.1002/cnr2.70691↗
  3. Effects of Pancreatic Duct Stenting on Nutrition and Pancreatic Function in Unresectable Pancreatic Cancer: A Pilot Study. Co-author DOI 10.1002/jgh3.70358↗
  4. Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarc… Co-author DOI 10.1007/s10147-026-03071-6↗
  5. Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routin… Co-author DOI 10.1007/s12094-025-04111-9↗
  6. KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006645↗
  7. Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01309-6↗
  8. Impact of zinc deficiency on the prognosis of unresectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.007↗
  9. Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer. Co-author DOI 10.1007/s10147-024-02544-w↗
  10. Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-024-73020-8↗
  11. Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer. Co-author DOI 10.1186/s12885-024-12722-8↗
  12. Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. Co-author DOI 10.1007/s00432-023-04966-x↗
  13. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. Co-author DOI 10.1186/s12885-023-11205-6↗
  14. Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. Co-author DOI 10.3390/cancers15030970↗
  15. Refractory Lower Limb Edema Resolved by Endovascular Stent Placement for Inferior Vena Cava Stenosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002152↗
  16. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic ca… Co-author DOI 10.1371/journal.pone.0264653↗
  17. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine an… Co-author DOI 10.3390/curroncol29040216↗
  18. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Ca… Co-author DOI 10.3390/cancers13184733↗
  19. Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesions. Co-author DOI 10.1097/mpa.0000000000001521↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenji Ikezawa · 19 shared papers, 2020–2026 · strength 3.55
  2. Kazuyoshi Ohkawa · 18 shared papers, 2021–2026 · strength 3.45
  3. Ryoji Takada · 17 shared papers, 2021–2026 · strength 3.25
  4. Yugo Kai · 17 shared papers, 2021–2026 · strength 3.25
  5. Takuo Yamai · 12 shared papers, 2020–2026 · strength 1.90
  6. Ko Watsuji · 7 shared papers, 2023–2026 · strength 1.34
  7. Yusuke Seiki · 7 shared papers, 2023–2026 · strength 1.34
  8. Kana Hosokawa · 4 shared papers, 2025–2026 · strength 0.96
  9. Yasuharu Kawamoto · 6 shared papers, 2022–2024 · strength 0.92
  10. Takumi Kinomoto · 3 shared papers, 2025–2026 · strength 0.71
  11. Hidenori Takahashi · 3 shared papers, 2021–2026 · strength 0.60
  12. Nobuyasu Fukutake · 3 shared papers, 2021–2026 · strength 0.52
  13. Kazuma Daiku · 4 shared papers, 2021–2022 · strength 0.52
  14. Shigenori Nagata · 2 shared papers, 2024–2026 · strength 0.43
  15. Yoji Kukita · 2 shared papers, 2023–2026 · strength 0.39
  16. Hirofumi Akita · 2 shared papers, 2021–2026 · strength 0.35
  17. Reiko Ashida · 2 shared papers, 2021–2026 · strength 0.31
  18. Shinichiro Hasegawa · 1 shared paper, 2026 · strength 0.25
  19. Hisataka Ogawa · 1 shared paper, 2026 · strength 0.25
  20. Tomoya Ekawa · 1 shared paper, 2026 · strength 0.25
  21. Hideaki Tahara · 1 shared paper, 2026 · strength 0.25
  22. Kunihito Gotoh · 1 shared paper, 2026 · strength 0.24
  23. Susumu Hijioka · 1 shared paper, 2026 · strength 0.20
  24. Taro Yamashita · 1 shared paper, 2026 · strength 0.20
  25. Kazuo Hara · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.